Expression of mir34a in Children with Progressive Familial Intrahepatic Cholestasis: A Cross-Sectional Study Based on Shiraz Pediatric Liver Cirrhosis Cohort Study

IF 0.4 4区医学 Q4 PEDIATRICS

Iranian Journal of Pediatrics Pub Date : 2024-02-17 DOI:10.5812/ijp-142943

N. Motazedian, Negar Azarpira, Kimia Falamarzi, Mohsen Dehghani, Maryam Ataollahi, Elaheh Esfandiari, Mahintaj Dara, Ali Shekarforoush, Mehrap Sayadi, Razieh Toobafard

{"title":"Expression of mir34a in Children with Progressive Familial Intrahepatic Cholestasis: A Cross-Sectional Study Based on Shiraz Pediatric Liver Cirrhosis Cohort Study","authors":"N. Motazedian, Negar Azarpira, Kimia Falamarzi, Mohsen Dehghani, Maryam Ataollahi, Elaheh Esfandiari, Mahintaj Dara, Ali Shekarforoush, Mehrap Sayadi, Razieh Toobafard","doi":"10.5812/ijp-142943","DOIUrl":null,"url":null,"abstract":"Background: Progressive familial intrahepatic cholestasis (PFIC) is a rare progressive liver disease associated with portal hypertension leading to liver failure. Most PFIC patients ultimately need liver transplantation. Therefore, identifying a precise, non-invasive biomarker for PFIC is very important. Objectives: This study aimed to investigate the microRNA-34a (miR-34a) expression levels in PFIC patients. Methods: A total of 18 PFIC patients were randomly selected from the Shiraz Pediatric Liver Cirrhosis Cohort Study (SPLCCS), and 18 healthy subjects were enrolled in this study. Blood samples were obtained, and the gene expression of Serum miR-34a was analyzed. Results: The results of this study showed that the serum level of miR-34a was significantly increased in PFIC patients, compared to the healthy group (P = 0.0327). However, no association was observed between miR-34a expression and clinical and laboratory findings of PFIC cases. Additionally, the results showed no correlation between miR-34a and serum levels of liver enzymes, albumin, gamma-glutamyl transpeptidase (GGT), and international normalized ratio (INR) among PFIC patients. Conclusions: miR-34a might be a beneficial, non-invasive target for PFIC diagnosis; however, further investigations with a larger population and longer duration are necessary to determine the potential of miR-34a as a diagnostic and therapeutic biomarker for PFIC.","PeriodicalId":14593,"journal":{"name":"Iranian Journal of Pediatrics","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijp-142943","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Progressive familial intrahepatic cholestasis (PFIC) is a rare progressive liver disease associated with portal hypertension leading to liver failure. Most PFIC patients ultimately need liver transplantation. Therefore, identifying a precise, non-invasive biomarker for PFIC is very important. Objectives: This study aimed to investigate the microRNA-34a (miR-34a) expression levels in PFIC patients. Methods: A total of 18 PFIC patients were randomly selected from the Shiraz Pediatric Liver Cirrhosis Cohort Study (SPLCCS), and 18 healthy subjects were enrolled in this study. Blood samples were obtained, and the gene expression of Serum miR-34a was analyzed. Results: The results of this study showed that the serum level of miR-34a was significantly increased in PFIC patients, compared to the healthy group (P = 0.0327). However, no association was observed between miR-34a expression and clinical and laboratory findings of PFIC cases. Additionally, the results showed no correlation between miR-34a and serum levels of liver enzymes, albumin, gamma-glutamyl transpeptidase (GGT), and international normalized ratio (INR) among PFIC patients. Conclusions: miR-34a might be a beneficial, non-invasive target for PFIC diagnosis; however, further investigations with a larger population and longer duration are necessary to determine the potential of miR-34a as a diagnostic and therapeutic biomarker for PFIC.

查看原文本刊更多论文

mir34a在进行性家族性肝内胆汁淤积患儿中的表达：基于设拉子小儿肝硬化队列研究的横断面研究

背景：进行性家族性肝内胆汁淤积症（PFIC）是一种罕见的进行性肝病，伴有门静脉高压，可导致肝功能衰竭。大多数 PFIC 患者最终需要接受肝移植。因此，确定 PFIC 的精确、非侵入性生物标志物非常重要。研究目的本研究旨在调查 PFIC 患者的 microRNA-34a (miR-34a) 表达水平。方法本研究从设拉子小儿肝硬化队列研究（SPLCCS）中随机选取了 18 名 PFIC 患者和 18 名健康受试者。研究人员采集了血液样本，并分析了血清 miR-34a 的基因表达。结果显示研究结果显示，与健康组相比，PFIC 患者的血清 miR-34a 水平明显升高（P = 0.0327）。然而，未观察到 miR-34a 的表达与 PFIC 病例的临床和实验室检查结果之间存在关联。此外，研究结果表明，miR-34a 与 PFIC 患者血清中的肝酶、白蛋白、γ-谷氨酰转肽酶（GGT）和国际正常化比值（INR）水平之间没有相关性。结论：miR-34a 可能是诊断 PFIC 的一个有益的非侵入性靶点；然而，要确定 miR-34a 作为 PFIC 诊断和治疗生物标志物的潜力，还需要进行更多人群和更长时间的进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian Journal of Pediatrics 医学-小儿科

CiteScore

0.90

自引率

20.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Iranian Journal of Pediatrics (Iran J Pediatr) is a peer-reviewed medical publication. The purpose of Iran J Pediatr is to increase knowledge, stimulate research in all fields of Pediatrics, and promote better management of pediatric patients. To achieve the goals, the journal publishes basic, biomedical, and clinical investigations on prevalent diseases relevant to pediatrics. The acceptance criteria for all papers are the quality and originality of the research and their significance to our readership. Except where otherwise stated, manuscripts are peer-reviewed by minimum three anonymous reviewers. The Editorial Board reserves the right to refuse any material for publication and advises that authors should retain copies of submitted manuscripts and correspondence as the material cannot be returned. Final acceptance or rejection rests with the Editors.